Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS) (TOMAS)
A Phase Ib Study on the Combination of Trabectedin and Olaparib in Unresectable Advanced/Metastatic Sarcomas After Failure of Standard Therapies
Sponsor: AstraZeneca
Listed as NCT02398058, this PHASE1 trial focuses on Bone Tumor and Soft Tissue Sarcoma and remains completed. Sponsored by AstraZeneca, it has been updated 11 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
May 2021 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE1
▶ Show 6 earlier versions
-
Sep 2019 — Jan 2021 [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
-
Mar 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE1
-
Dec 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE1
-
Apr 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Apr 2017 [monthly]
Recruiting PHASE1
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Istituto Di Ricerche Farmacologiche Mario Negri
- Italian Sarcoma Group
- PharmaMar
For direct contact, visit the study record on ClinicalTrials.gov .